Skip to main content
CLVSinactive

Clovis Oncology, Inc.

Biopharma developer (SEC filing verified)·Commercial
Oncology

CLVS evidence brief

What we can confirm

BioSniper Score:
7.3 / 10
Lead Asset:
lucitanib (Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 7.3 / 10 · Lead Asset: lucitanib (Phase 2)
BioSniper AIPage context preserved

Prepared research question

What matters most for CLVS—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

7.3/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

lucitanib (Phase 2)

Next Catalyst

—

Tracking 2 pipeline candidates for Clovis Oncology, Inc..

Run Clovis Oncology, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Clovis Oncology, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is Clovis Oncology, Inc.'s lead drug candidate?

Clovis Oncology, Inc.'s most advanced tracked candidate is lucitanib (Phase 2).

What therapeutic areas does Clovis Oncology, Inc. focus on?

Clovis Oncology, Inc. develops therapies across Oncology.

925 active companies304,861 SEC filings22,725 clinical trials
Citation log window (7 days): 13,334 recorded LLM calls; 0 block events, 0 warning events. These counts do not measure factual accuracy or research quality.Computed at
How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.